International Experts to Present on Avita Medical''s Regenerative Medicine Approach at Medical Symposium, London
(firmenpresse) - NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM -- (Marketwired) -- 04/22/16 -- Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specialising in the treatment of wounds and skin defects, today announced that Mr Paul Hayes, Vascular Surgeon at Addenbrooke''s Hospital, UK and Mr Harvey Chant, Vascular Surgeon, The Royal Cornwall Hospital, UK will present on their experience and data on the use of Avita''s ReGenerCell™ in wound care at the Charing Cross International Symposium at Olympia Grand, London, UK from 26-29 April. This year''s programme will focus on the challenges in the vascular and endovascular field.
Details of the sessions are as follows:
The Use of Autologous Cell Suspension for Complex Diabetic Wounds
Mr Harvey Chant
Mini-symposium: Wound Healing
Upper Main Auditorium
Tuesday 26 April
17.16 - 17.24
A Pilot Randomised Controlled Trial of ReGenerCell™ for the Treatment of Venous Leg Ulcers
: Mr Paul Hayes
C Innovation Showcase
Olympia Room
Wednesday 27 April
13.40 - 13.50
The Use of Autologous Cell Suspension in Wound Healing
Mr Harvey Chant
CX ilegx Collaboration Day
Pillar Hall
Thursday 28 April
08.52 - 09.30
The Charing Cross Symposium first took place in 1978 at Charing Cross Hospital, Hammersmith, London, and is the longest running vascular and endovascular symposium in Europe and one of the largest in the world.
This year''s symposium focuses on challenges in complete optimal vascular disease management, catering for all vascular specialists.
For further information, visit:
Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita''s patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient''s own skin. The Company''s regenerative product portfolio includes ReCell® for burns aimed at plastic reconstructive procedures, ReGenerCell™ for chronic wounds and ReNovaCell™ of restoration of pigmentation and cosmesis. ReCell®, ReGenerCell™ and ReNovaCell™ are patented, CE-marked for Europe. ReCell® is TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. trial is well underway aimed at securing FDA approval.
To learn more, visit .
Adam Kelliher
Chief Executive Officer
Phone: +44 (0) 1763 269770
Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
Gabriel Chiappini
Company Secretary
Phone +61(0) 8 9474 7738
Gemma Howe/Sue Charles
Phone +44 (0)20 7866 7860
Lee Roth, Investor Relations
Kirsten Thomas, Public Relations
Phone: +1 (646) 536-7012 / +1 (508) 280-6592
/
Rudi Michelson
Investor Relations / PR
Phone: +61 3 9620 3333
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.04.2016 - 04:00 Uhr
Sprache: Deutsch
News-ID 1429885
Anzahl Zeichen: 3519
contact information:
Contact person:
Town:
NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM
Phone:
Kategorie:
Medical Devices
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 297 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"International Experts to Present on Avita Medical''s Regenerative Medicine Approach at Medical Symposium, London
"
steht unter der journalistisch-redaktionellen Verantwortung von
Avita Medical (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
